Alzamend Neuro, Inc. (ALZN) News
Track canonical SquawkNews coverage tagged to ALZN, Alzamend Neuro, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 10 indexed stories across 9 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Alzamend Neuro presents Phase 1/2A 7T lithium imaging results showing trends favoring AL001
Alzamend Neuro presented Phase 1/2A 7T brain pharmacokinetic imaging data showing trends toward higher brain lithium levels and AUC for AL001 versus lithium carbonate.Key Highlights:Original SEC Filing: Alzamend Neuro, I
REGULATION | Sep 29, 2026, 10:33 AM UTC
H
Alzamend Neuro Inc reports results for the quarter ended April 30 - Earnings Summary
FORECAST CHANGESRECOMMENDATIONSThis summary was machine generated from LSEG data September 14 at 09:01 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, cont
EARNINGS | Sep 14, 2026, 09:01 PM UTC
H
Alzamend Neuro Inc expected to post a loss of 23 cents a share - Earnings Preview
Alzamend Neuro Inc expected to post a loss of 23 cents a share - Earnings Preview
EARNINGS | Sep 11, 2026, 08:03 PM UTC
M
Alzamend Neuro posts $3.03M quarterly net loss
For the quarter ended July 31, 2026, Alzamend Neuro reported a net loss of $3.03M and diluted net loss per share of $(0.68). The company recorded no product revenue.
EARNINGS | Sep 10, 2026, 08:42 PM UTC
M
ALZN reports $3.0 million quarterly net loss and $7.6 million cash
ALZN said its net loss widened to $3.0 million for the quarter. The company reported cash increased to $7.6 million after equity financing, while citing substantial doubt about continuing as a going concern.
EQUITY | Sep 10, 2026, 08:35 PM UTC
L
Alzamend Neuro expected loss of 56 cents a share
Alzamend Neuro Inc is expected to post a loss of 56 cents a share.
EARNINGS | Sep 04, 2026, 08:07 PM UTC
L
Alzamend Neuro’s Phase 1/2A lithium neuroimaging data accepted for poster
Alzamend Neuro’s Phase 1/2A lithium neuroimaging data has been accepted for poster presentation at Neuroscience 2026 in Washington, DC, per TradeXchange Newsdesk.
EQUITY | Aug 20, 2026, 12:01 PM UTC
L
Alzamend Neuro lithium imaging data accepted for oral presentation
Alzamend Neuro says its Phase 1/2A lithium imaging data has been accepted for an oral presentation at the ISMRM Workshop on X-Nuclei MR in Barcelona, Spain.
EQUITY | Aug 18, 2026, 12:01 PM UTC
L
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Can Fite Biopharma (AMEX: CANF ) stock moved upwards by 52.0% to $4.52 during Wednesday's pre-market session. The company's market cap stands at $6.3 million. Atlantic International (NASDAQ: ATLN ) shares rose 17
EQUITY | Jul 01, 2026, 12:05 PM UTC
L
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Alzamend Neuro (NASDAQ: ALZN ) stock increased by 12.9% to $1.35 during Tuesday's after-market session. The company's market cap stands at $4.4 million. Vivos Therapeutics (NASDAQ: VVOS ) shares increased by 9.92
GEOPOLITICS | Jun 30, 2026, 09:05 PM UTC